Biodexa Pharmaceuticals Plc SEC filings BDRX
Biodexa Pharmaceuticals Plc has 731 filings in SEC EDGAR's recent list, going back to Jun 4, 2015. Its latest annual report, Form 20-F, was filed on Mar 27, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 14, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Sep 30, 2026 | — |
| EFFECT | Filing | Aug 3, 2026 | — |
| EFFECT | Filing | Mar 30, 2026 | — |
| EFFECT | Filing | Mar 30, 2026 | — |
| EFFECT | Filing | Mar 30, 2026 | — |
| EFFECT | Filing | Mar 30, 2026 | — |
| EFFECT | Filing | Mar 30, 2026 | — |
| EFFECT | Filing | Mar 30, 2026 | — |
| EFFECT | Filing | Dec 17, 2025 | — |
| CORRESP | Letter to the SEC | Dec 17, 2025 | — |
| CORRESP | Letter to the SEC | Dec 17, 2025 | — |
| EFFECT | Filing | Nov 21, 2025 | — |
| EFFECT | Filing | Nov 21, 2025 | — |
| CORRESP | Letter to the SEC | Nov 17, 2025 | — |
| EFFECT | Filing | Sep 30, 2025 | — |
| CORRESP | Letter to the SEC | Sep 29, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 29, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 20, 2025 | — |
| CORRESP | Letter to the SEC | Aug 19, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 18, 2025 | — |
| EFFECT | Filing | May 9, 2025 | — |
| EFFECT | Filing | May 9, 2025 | — |
| EFFECT | Filing | May 9, 2025 | — |
| UPLOAD | Letter from the SEC | May 9, 2025 | — |
| DRSLTR | Filing | May 1, 2025 | — |
| DRS | Filing | May 1, 2025 | — |
| EFFECT | Filing | Jan 27, 2025 | — |
| CORRESP | Letter to the SEC | Jan 23, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 23, 2025 | — |
| EFFECT | Filing | Aug 19, 2024 | — |
| CORRESP | Letter to the SEC | Aug 15, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 15, 2024 | — |
| D | Filing | Aug 1, 2024 | — |
| EFFECT | Filing | Jun 14, 2024 | — |
| CORRESP | Letter to the SEC | Jun 11, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 11, 2024 | — |
| EFFECT | Filing | May 2, 2024 | — |
| EFFECT | Filing | May 2, 2024 | — |
| EFFECT | Filing | May 2, 2024 | — |
| EFFECT | Filing | May 2, 2024 | — |
| EFFECT | Filing | Mar 27, 2024 | — |
| CORRESP | Letter to the SEC | Mar 20, 2024 | — |
| UPLOAD | Letter from the SEC | Mar 20, 2024 | — |
| D | Filing | Jan 4, 2024 | — |
| EFFECT | Filing | Dec 18, 2023 | — |
| CORRESP | Letter to the SEC | Dec 15, 2023 | — |
| CORRESP | Letter to the SEC | Dec 15, 2023 | — |
| UPLOAD | Letter from the SEC | Oct 12, 2023 | — |
| EFFECT | Filing | Jun 28, 2023 | — |
| EFFECT | Filing | Jun 26, 2023 | — |
| CORRESP | Letter to the SEC | Jun 23, 2023 | — |
| UPLOAD | Letter from the SEC | Jun 21, 2023 | — |
| D | Filing | Jun 7, 2023 | — |
| EFFECT | Filing | Jun 1, 2023 | — |
| CORRESP | Letter to the SEC | May 25, 2023 | — |
| UPLOAD | Letter from the SEC | May 22, 2023 | — |
| EFFECT | Filing | Mar 24, 2023 | — |
| CORRESP | Letter to the SEC | Mar 16, 2023 | — |
| UPLOAD | Letter from the SEC | Mar 15, 2023 | — |
| D | Filing | Feb 17, 2023 | — |
| EFFECT | Filing | Oct 26, 2022 | — |
| CORRESP | Letter to the SEC | Oct 24, 2022 | — |
| UPLOAD | Letter from the SEC | Oct 24, 2022 | — |
| SD | Specialized disclosure (conflict minerals) | May 26, 2022 | — |
| EFFECT | Filing | Apr 29, 2022 | — |
| EFFECT | Filing | Jun 4, 2021 | — |
| 8-A12B/A | Amendment no. 1 | Apr 30, 2021 | — |
| EFFECT | Filing | Aug 13, 2020 | — |
| UPLOAD | Letter from the SEC | Aug 11, 2020 | — |
| CORRESP | Letter to the SEC | Aug 11, 2020 | — |
| D | Filing | Jun 4, 2020 | — |
| SD | Specialized disclosure (conflict minerals) | May 6, 2020 | — |
| D | Filing | Nov 7, 2019 | — |
| EFFECT | Filing | Oct 21, 2019 | — |
| CORRESP | Letter to the SEC | Oct 17, 2019 | — |
| CORRESP | Letter to the SEC | Oct 11, 2019 | — |
| UPLOAD | Letter from the SEC | Oct 3, 2019 | — |
| SD | Specialized disclosure (conflict minerals) | May 14, 2019 | — |
| SD | Specialized disclosure (conflict minerals) | May 30, 2018 | — |
| CT ORDER | Filing | May 16, 2018 | — |
| CT ORDER | Filing | Aug 22, 2017 | — |
| CT ORDER | Filing | Aug 15, 2017 | — |
| CT ORDER | Filing | May 3, 2017 | — |
| CT ORDER | Filing | Jun 2, 2016 | — |
| CERTNAS | Auto-generated paper document | Dec 3, 2015 | — |
| 8-A12B | Filing | Dec 2, 2015 | — |
| 425 | Filing | Nov 2, 2015 | — |
| EFFECT | Filing | Oct 30, 2015 | — |
| EFFECT | Filing | Oct 22, 2015 | — |
| CORRESP | Letter to the SEC | Oct 20, 2015 | — |
| CORRESP | Letter to the SEC | Oct 8, 2015 | — |
| UPLOAD | Letter from the SEC | Oct 6, 2015 | — |
| CORRESP | Letter to the SEC | Sep 22, 2015 | — |
| UPLOAD | Letter from the SEC | Sep 8, 2015 | — |
| 425 | Filing | Aug 12, 2015 | — |
| 425 | Filing | Jun 5, 2015 | — |
| 425 | Filing | Jun 5, 2015 | — |
| 425 | Filing | Jun 5, 2015 | — |
| 425 | Filing | Jun 4, 2015 | — |
Showing 99 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BDRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- United Kingdom
- Headquarters
- Cardiff
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1643918
- Former names
- Midatech Pharma Plc (until Mar 27, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.